IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科
学科主题临床医学
A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China
Yang, Lu1; Wang, Zhi-jie1; An, Tong-tong1; Bai, Hua1; Zhao, Jun1; Duan, Jian-chun1; Li, Ping-ping2; Wu, Mei-na1; Sun, Hong2; Liang, Li3; Wang, Jie1
关键词Gefitinib Maintenance therapy Non-small cell lung cancer
刊名CHINESE JOURNAL OF CANCER RESEARCH
2010-03-01
DOI10.1007/s11670-010-0001-3
22期:1页:1-9
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者National "863" High Technology Research and Development Program of China ; Capital Development Foundation of Beijing ; National "863" High Technology Research and Development Program of China ; Capital Development Foundation of Beijing
研究领域[WOS]Oncology
关键词[WOS]GROWTH-FACTOR RECEPTOR ; PREVIOUSLY TREATED PATIENTS ; RANDOMIZED-TRIAL ; SUPPORTIVE CARE ; MULTICENTER ; MUTATIONS ; DOCETAXEL ; ERLOTINIB ; SURVIVAL ; PLACEBO
英文摘要

To investigate the efficacy and safety of gefitinib as maintenance therapy for advanced non-small cell lung cancer (NSCLC) patients who obtained disease control (DC) after first-line chemotherapy in Chinese population.

Chinese patients with advanced NSCLC treated with standard chemotherapy and obtained DC were assigned to receive gefitinib as maintenance treatment. The primary end point was overall survival time (OS), the second end point was disease control rate (DCR) and progression-free survival time (PFS). DCR included complete response (CR) plus partial response (PR) and plus stable disease (SD). The impact of epidermal growth factor receptor (EGFR) mutation status on the treatment as exploratory point was also evaluated by denaturing high-performance liquid chromatography (DHPLC).

Among 75 enrolled patients, the overall response rate was 37% and the DCR (CR + PR +SD) was 66%. The median PFS and OS were 17.13 months and 26.13 months respectively, with 1- and 2-year survival rates 89.3% and 34.7%. Patients harboring somatic EGFR mutations obtained a prolonged median PFS and OS compared with EGFR wide type (25.1 vs. 13.0 months, P=0.019 and 33.37 vs. 25.57 months, P=0.014, respectively). In COX regression model, only EGFR mutation status was the independently factor influencing both PFS and OS (P=0.029 and 0.017, respectively), however, rash status was the predictor in terms of PFS (P=0.027).

Gefitinib produced encouraging survival when delivered as maintenance therapy in Chinese patients obtaining DC after first-line chemotherapy, especially for patients carrying somatic EGFR mutations. EGFR mutation is an independently predictive factor of survival.

语种英语
所属项目编号2006AA02A401 ; 30772472
资助者National "863" High Technology Research and Development Program of China ; Capital Development Foundation of Beijing ; National "863" High Technology Research and Development Program of China ; Capital Development Foundation of Beijing
WOS记录号WOS:000274464600001
Citation statistics
Cited Times:1[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65108
Collection北京大学临床肿瘤学院_胸部肿瘤内科
作者单位1.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Thorac Med Oncol, Beijing 100142, Peoples R China
2.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Tradit Chinese Med Combined W Med Oncol, Beijing 100142, Peoples R China
3.Peking Univ, Hosp 3, Dept Oncol, Beijing 100083, Peoples R China
Recommended Citation
GB/T 7714
Yang, Lu,Wang, Zhi-jie,An, Tong-tong,et al. A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China[J]. CHINESE JOURNAL OF CANCER RESEARCH,2010,22(1):1-9.
APA Yang, Lu.,Wang, Zhi-jie.,An, Tong-tong.,Bai, Hua.,Zhao, Jun.,...&Wang, Jie.(2010).A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China.CHINESE JOURNAL OF CANCER RESEARCH,22(1),1-9.
MLA Yang, Lu,et al."A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China".CHINESE JOURNAL OF CANCER RESEARCH 22.1(2010):1-9.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Yang, Lu]'s Articles
[Wang, Zhi-jie]'s Articles
[An, Tong-tong]'s Articles
百度学术
百度学术Similar articles in
[Yang, Lu]'s Articles
[Wang, Zhi-jie]'s Articles
[An, Tong-tong]'s Articles
必应学术
必应学术Similar articles in
[Yang, Lu]'s Articles
[Wang, Zhi-jie]'s Articles
[An, Tong-tong]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.